VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management
Status:
Unknown status
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The investigators aimed to use pharmacogenetic information in clinical practise which may
lead to rapid, efficient, and safe warfarin dosing in this observational prospective study.
In this context, the investigators plan to develop an algorithm for estimating the
appropriate warfarin dose that is based on both clinical and genetic data from the Turkish
study population. This study is unique not only investigating clinical factors, demographic
variables, CYP2C9, and VKORC1 gene variations which contribute to the variability among
patients in dose requirements for warfarin but also including thrombogenic single nucleotide
polymorphisms (SNP) in the same patient population. Thus, warfarin would be a good example by
being the first cardiovascular drug for pharmacogenetic guided "personalized medicine"
applications.